Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to make presentations at the following upcoming events: Jefferies 2018 Global Healthcare Conference – New York , June 5-8, 2018 June 6 , 3:30 p.m.

Arrowhead Pharmaceuticals to Present at Upcoming June 2018 Conferences

Pasadena. CA | Posted on May 31st, 2018

June 6, 3:30 p.m. EDT –Chris Anzalone, Ph.D., Arrowhead’s president and chief executive officer, will present a corporate overview

41stEuropean Cystic Fibrosis Conference– Belgrade, Serbia, June 6-9, 2018

June 6, 5:55 p.m. CET –Erik Bush, Ph.D., Arrowhead’s director of extra-hepatic targeting, will deliver an oral presentation titled, “Targeting αENaC with an epithelial RNAi trigger delivery platform for the treatment of cystic fibrosis”

The Science of HBV Cure 2018 – Suntec City, Singapore, June 8-9, 2018

June 8, 5:30 p.m. SGT –Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver an oral presentation titled, “Hitting HBV everywhere; why RNAi holds so much potential as a platform therapy in CHB”

Global Hepatitis Summit 2018 – Toronto, June 14-17, 2018

June 15, 2:15 p.m. EDT –Christine Wooddell, Ph.D., Arrowhead’s director of liver targeting, will deliver an oral presentation titled, “Interferon-gamma pathway is activated in a chronically HBV infected chimpanzee that controls HBV following ARC-520 RNAi treatment”

JMP Securities Life Sciences Conference– New York, June 20-21, 2018

June 20, 9:00 a.m. EDT –Bruce Given, M.D., will present a corporate overview

27th Annual Alpha-1 National Education Conference– San Francisco, June 29 - July 1, 2018

June 29, 3:45 p.m. PDT –Bruce Given, M.D., will deliver an oral presentation titled, “Development of ARO-AAT, an RNAi based therapeutic for Alpha-1 antitrypsin deficiency-related liver disease”

A copy of presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website after the presentations conclude.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400

or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

Breakthrough material could lead to cheaper, more widespread solar panels and electronics July 16th, 2019

Caught in the act: Images capture molecular motions in real time July 15th, 2019

NUS ‘smart’ textiles boost connectivity between wearable sensors by 1,000 times: Metamaterials are incorporated into conventional clothing to dramatically improve signal strength between electronic devices, allowing for new applications July 15th, 2019

Possible Futures

Breakthrough material could lead to cheaper, more widespread solar panels and electronics July 16th, 2019

Caught in the act: Images capture molecular motions in real time July 15th, 2019

Dresden physicists use nanostructures to free photons for highly efficient white OLEDs: Trapped light particles July 12th, 2019

Strange warping geometry helps to push scientific boundaries July 12th, 2019

Investments/IPO's/Splits

Picosun accelerates growth with a notable Finnish investment June 28th, 2019

Nanometrics and Rudolph Technologies to Jointly Participate in the 11th Annual CEO Investor Summit 2019 June 27th, 2019

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) June 22nd, 2019

Nanomedicine

An 'EpiPen' for spinal cord injuries July 12th, 2019

Nanotechnology delivers hepatitis B vaccine: X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response. The material can give rise to a polyvaccine against six diseases July 12th, 2019

Sheaths drive powerful new artificial muscles July 11th, 2019

Nanotechnology pioneer Chad Mirkin wins Kabiller Prize in Nanoscience and Nanomedicine: Molly Stevens of Imperial College London receives Kabiller Young Investigator Award July 11th, 2019

Announcements

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

Breakthrough material could lead to cheaper, more widespread solar panels and electronics July 16th, 2019

Caught in the act: Images capture molecular motions in real time July 15th, 2019

NUS ‘smart’ textiles boost connectivity between wearable sensors by 1,000 times: Metamaterials are incorporated into conventional clothing to dramatically improve signal strength between electronic devices, allowing for new applications July 15th, 2019

Events/Classes

Nanometrics to Announce Second Quarter Financial Results on July 30, 2019 July 17th, 2019

Arrowhead Pharmaceuticals to Present at Upcoming June 2019 Conferences June 2nd, 2019

ACS selects Naomi Halas to represent Americas at ChinaNano: Rice U. pioneer wins 2019 ACS Nano Lectureship Award for the Americas May 29th, 2019

CEA-Leti Develops CMOS Process for High-Performance MicroLEDs That Could Overcome Display-Size Obstacles: New Concept Creates All-in-One RGB MicroLEDs, Eliminates Several Transfer Steps to Receiving Substrate & Boosts Performance May 16th, 2019

Nanobiotechnology

An 'EpiPen' for spinal cord injuries July 12th, 2019

Nanotechnology delivers hepatitis B vaccine: X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response. The material can give rise to a polyvaccine against six diseases July 12th, 2019

Nanotechnology pioneer Chad Mirkin wins Kabiller Prize in Nanoscience and Nanomedicine: Molly Stevens of Imperial College London receives Kabiller Young Investigator Award July 11th, 2019

Imprinted spheres fight breast cancer: Inhibition of HER2 on tumor cells by molecularly imprinted nanoparticles July 9th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project